[CD4+, CD8+ AND CD19+ cells in individuals with dyslipidemia].

Area of Science:

• Immunology
• Cardiovascular Science
• Biochemistry

Context:

• Inflammatory mechanisms are increasingly recognized in atherosclerosis pathogenesis.
• Plasma markers of inflammation are studied as cardiovascular risk predictors.
• Few studies have investigated the role of specific inflammatory cells, like T and B lymphocytes, in atherosclerosis.

Purpose:

• To determine the percentage of peripheral inflammatory cells in dyslipidemic individuals compared to a control group using flow cytometry.
• To investigate the specific roles of CD4+, CD8+, and CD19+ cells in dyslipidemia-related atherosclerosis.

Summary:

• Flow cytometry analysis revealed a significant reduction in CD4+ T cells in dyslipidemic individuals.
• No significant differences were observed in the percentages of CD8+ T cells and CD19+ B cells between groups.
• The study noted limitations due to small sample size but indicated potential reduction of certain molecules with acetylsalicylic acid treatment.

Impact:

• Highlights the potential role of CD4+ T cell reduction in dyslipidemia-associated atherosclerosis.
• Suggests a need for further research into T and B lymphocyte subtypes (Th1, Th2, regulatory T cells) in atherosclerosis.
• Provides preliminary evidence for the therapeutic potential of acetylsalicylic acid in modulating inflammatory markers in dyslipidemia.